BackTcr2 Therapeutics Overview

Tcr2 Therapeutics Total Liabilities

Tcr2 Therapeutics's total liabilities is $50M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$50.18M
↓ 26.13% YoYΔ $-17.75M vs prior year quarter

Peer trimmed avg / median

Loading

Tcr2 Therapeutics Total Liabilities History

Loading

Tcr2 Therapeutics vs. peers: Total Liabilities Comparison

Loading

Tcr2 Therapeutics Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Tcr2 Therapeutics (TCRR) FAQ

Tcr2 Therapeutics's total liabilities stands at $50M as of March 2023. That compares with $68M in the prior-year period — down 26.1% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Tcr2 Therapeutics reported $50M in total liabilities versus $68M a year earlier — a 26.1% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $68M in the prior-year period — down 26.1% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Tcr2 Therapeutics's total liabilities evolved across reporting periods, while the comparison chart places TCRR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total liabilities is commonly used to spot outliers. Tcr2 Therapeutics's reading of $50M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.